UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF
THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER
SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 1-15609
Agouron Pharmaceuticals, Inc.
(Exact name of registrant as specified in its
charter) 10350 North Torrey Pines Road, La Jolla,
California 92037-1020
(619) 622-3000
(Address, including zip code, and telephone number,
including area code, of registrant's
principal executive offices)
Common Stock, without par value
(Titles of all other classes of securities for which a duty to file reports
under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule
provision(s) relied upon to terminate or suspend the duty to file reports:
Rule 12g-4(a)(1)(i) \x\ Rule 12h-3(b)(1)(i) \x\
Rule 12g-4(a)(1)(ii) \ \ Rule 12h-3(b)(1)(ii) \ \
Rule 12g-4(a)(2)(i) \ \ Rule 12h-3(b)(2)(i) \ \
Rule 12g-4(a)(2)(ii) \ \ Rule 12h-3(b)(2)(ii) \ \
Rule 15d-6
Approximate number of holders of record as of the certification or notice date:
One
Pursuant to the requirements of the Securities Exchange Act of 1934
Agouron Pharmaceuticals, Inc. has caused this certification/notice to be signed
on its behalf by the undersigned duly authorized person.
Date: May 17, 1999 By: /s/
Name: Gary E. Friedman
Title: Secretary
